Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer

Adjuvant therapy for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer (EBC) remains challenging. The prognostic significance of HER2-low positivity in these patients is not fully understood. In our retrospectiv...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2023-11, Vol.13 (1), p.19669-19669, Article 19669
Main Authors: Shikata, Shohei, Murata, Takeshi, Yoshida, Masayuki, Hashiguchi, Hiromi, Yoshii, Yukiko, Ogawa, Ayumi, Watase, Chikashi, Shiino, Sho, Sugino, Hirokazu, Jimbo, Kenjiro, Maeshima, Akiko, Iwamoto, Eriko, Takayama, Shin, Suto, Akihiko
Format: Article
Language:English
Subjects:
692/4028/67/1347
692/53/2422
Breast cancer
ErbB-2 protein
Humanities and Social Sciences
Lymph nodes
multidisciplinary
Science
Science (multidisciplinary)
Survival
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adjuvant therapy for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer (EBC) remains challenging. The prognostic significance of HER2-low positivity in these patients is not fully understood. In our retrospective study, we analyzed 647 patients with HR-positive, HER2-negative, node-positive EBC, stratifying them into three cohorts based on axillary lymph node involvement, tumor size, and characteristics. Cohort 1 included patients with either ≥ 4 positive axillary lymph nodes or 1–3 positive nodes with histological grade 3 or tumor size ≥ 5 cm. Cohort 2 consisted of patients with 1–3 positive nodes, histological grade
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-023-47033-8